bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

Contributed by: Business Wire

Logo

Images

bit.bio's cell therapy pipeline November 2023 (Graphic: Business Wire)

Business Wire embedded0

Tags

Technology

Pharmaceutical

Neurology

Oncology

Other Science

Research

Genetics

Clinical Trials

Finance

Biotechnology

Professional Services

Health

Stem Cells

General Health

Science

Other Manufacturing

Other Technology

Diabetes

Chemicals/Plastics

Surgery

Manufacturing

Other Health

Biometrics

Therapeutics

More Like This

(Graphic: Business Wire)

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

CRISPR-Ready ioGlutamatergic Neurons (Graphic: Business Wire)

bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery

ioMotor Neurons (Photo: Business Wire)

bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023